Pegvaliase

CHEMBL4297802 Phase 4 معتمد Enzyme
Half-Life
Bioavailability
Protein Binding
Molecular Weight
318.4 g/mol
LogP
-2.3
Phase
4

This enzyme therapy treats phenylketonuria (PKU) by providing a functional enzyme to lower phenylalanine levels.

الوزن الجزيئي

318,4100 g/mol

LogP

-2,30

TPSA

111,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

Pharmacokinetics (PK)

Pharmacodynamics (PD)

SMILES

COCCOCCCCCC(=O)NCCCC[C@@H](C(=O)O)N

InChI

InChI=1S/C15H30N2O5/c1-21-11-12-22-10-6-2-3-8-14(18)17-9-5-4-7-13(16)15(19)20/h13H,2-12,16H2,1H3,(H,17,18)(H,19,20)/t13-/m0/s1

Molecular Formula

C15H30N2O5

HBD / HBA

3 / 6

الروابط القابلة للدوران

15

الذرات الثقيلة

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This enzyme therapy treats phenylketonuria (PKU) by providing a functional enzyme to lower phenylalanine levels.

Yes, Pegvaliase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297802. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 86278362. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.